Search

Your search keyword '"Lengliné E"' showing total 66 results

Search Constraints

Start Over You searched for: Author "Lengliné E" Remove constraint Author: "Lengliné E"
66 results on '"Lengliné E"'

Search Results

1. Prognostic value of PET / CT and CT in T‐cell lymphoblastic lymphoma/leukaemia patients: A retrospective cohort study of 145 patients

2. Characteristics and outcomes of patients with acute myeloid leukemia admitted to intensive care unit with acute respiratory failure: a post-hoc analysis of a prospective multicenter study.

4. Prognostic value of PET/CT and CT in T‐cell lymphoblastic lymphoma/leukaemia patients: A retrospective cohort study of 145 patients.

6. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19

7. Caractéristiques cliniques, évolution à long terme et facteurs prédictifs de rechute après arrêt de l’Imatinib au cours de leucémie chronique à éosinophiles associée au réarrangement FIP1L1-PDGFRA : étude rétrospective à propos de 151 patients

8. Caractéristiques cliniques, évolution à long terme et facteurs prédictifs de rechute après arrêt de l’Imatinib au cours de leucémie chronique à éosinophiles associée au réarrangement FIP1L1-PDGFRA: étude rétrospective à propos de 151 patients

9. French Intensive Care Society, International congress - Réanimation 2016

10. French Intensive Care Society, International congress – Réanimation 2016

11. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients.

12. Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1+ acute lymphoblastic leukemia.

13. Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS).

14. Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission.

15. Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-cell acute lymphoblastic leukemia.

16. Outcomes of intracranial hemorrhage in critically ill patients with acute leukemia: Results of a retrospective cohort study.

17. [The transparency committee of the French National Authority for Health].

18. Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health.

20. Enriching single-arm clinical trials with external controls: possibilities and pitfalls.

21. Characteristics and outcomes of patients with acute myeloid leukemia admitted to intensive care unit with acute respiratory failure: a post-hoc analysis of a prospective multicenter study.

22. Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience.

23. Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis.

25. Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia.

26. The use of ICU resources in CAR-T cell recipients: a hospital-wide study.

27. Semen Cryopreservation in Adolescents and Young Adults with Hematologic Diseases: from Bed to Benchside.

28. Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications.

29. Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy.

30. Successful nelarabine and venetoclax treatment of a relapsed/refractory mediastinal myeloid sarcoma with clonal TCR rearrangement.

31. Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment.

32. Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL.

33. Identification of Distinct Immunophenotypes in Critically Ill Coronavirus Disease 2019 Patients.

34. IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL.

35. Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy.

36. Impact of immunosuppression on mortality in critically ill COVID-19 patients.

37. Trajectories of acute graft-versus-host disease and mortality in critically ill allogeneic-hematopoietic stem cell recipients: the Allo-GRRR-OH score.

38. Preclinical efficacy of humanized, non-FcγR-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia.

39. Clinical phenotypes of critically ill COVID-19 patients.

41. Neutropenic Enterocolitis in Critically Ill Patients: Spectrum of the Disease and Risk of Invasive Fungal Disease.

42. Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL.

44. Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia.

45. PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome.

46. The effect of age in patients with acquired aplastic anaemia treated with immunosuppressive therapy: comparison of Adolescents and Young Adults with children and older adults.

47. Determinants of 1-year survival in critically ill acute leukemia patients: a GRRR-OH study.

48. Gastrointestinal emergencies in critically ill cancer patients.

49. Graft-Versus-Host Disease in Adolescents and Young Adults (15-24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission.

50. Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia.

Catalog

Books, media, physical & digital resources